Boston Scientific Corporation $BSX Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 11.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 228,937 shares of the medical equipment provider’s stock after selling 29,392 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Boston Scientific were worth $24,590,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. GAMMA Investing LLC increased its position in shares of Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares in the last quarter. MRA Advisory Group purchased a new position in Boston Scientific in the 2nd quarter valued at $273,000. Bank of New Hampshire boosted its stake in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd grew its holdings in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after buying an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. acquired a new stake in shares of Boston Scientific in the second quarter valued at about $1,133,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 175,782 shares of company stock valued at $17,742,314 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.4%

BSX stock opened at $96.63 on Friday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The firm has a market cap of $143.25 billion, a PE ratio of 51.68, a PEG ratio of 2.02 and a beta of 0.58. The firm’s 50 day moving average price is $99.09 and its 200-day moving average price is $102.43. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BSX shares. Truist Financial boosted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, October 22nd. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Finally, Barclays boosted their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.